Piper Sandler analyst Biren Amin initiated coverage of BridgeBio Oncology (BBOT) with an Overweight rating and $21 price target The company is developing next-generation inhibitors of RAS-signaling targeting several types of solid tumors with significant market sizes, the analyst tells investors in a research note. The firm believes early results for BO-8520 have showed signals of “best-in-class” efficacy and safety in second-line G12C-mutant non-small cell lung cancer that ultimately could support front line use with peak sales potential of $600M.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT: